

Company Profile Fact Sheet

Commitment to Research, Development and Innovation

- Prolacta Bioscience is a privately-held life sciences company dedicated to Advancing the Science of Human Milk®. The company was founded in 1999 and has made significant investments in research and development, clinical studies and world-class manufacturing facilities for its Neonatal Nutritional Products to bring the healing power of breast milk to the most fragile preemies.
- Prolacta's first commercial product, Prolacta+ H²MF®, a human milk fortifier made exclusively with 100 percent donor breast milk, became available to hospitals by prescription in the Neonatal Intensive Care Unit (NICU) in 2006.
- Today, Prolacta is the world leader in providing human milk products to hospitals. Prolacta develops clinically proven, high-quality products derived from human milk that are designed to meet the needs of extremely premature infants in the NICU.
- When used as part of an exclusive human milk diet, Prolacta's Neonatal Nutritional Products are clinically proven^{i,ii,iii} to improve health outcomes and reduce healthcare system costs^v for critically ill preemies in the NICU.
- To further advance the science of human milk, Prolacta founded the International Conference on Human Milk Science and Innovation, a forum covering the latest in scientific and clinical research related to human milk. Renowned scientists and neonatologists from around the world attend this annual event.

Prolacta's Neonatal Nutritional Products are Improving the Standard of Care

- Hospitals choose Prolacta's Neonatal Nutritional Products for the assurance that they are receiving safe, standardized donor milk formulations processed in a pharmaceutical-grade facility, under the strictest quality and safety guidelines, to protect the health and well-being of their most fragile patients.
- Prolacta plays a vital role in helping hospitals meet the American Academy of Pediatrics' recommendation that all preterm infants be fed human milk whether mother's own milk or pasteurized donor human milk when mother's own milk is unavailable; for infants weighing less than 1500 grams, appropriate fortification is also recommended.^{vi}
- Increasing clinical evidence has led to greater hospital demand for exclusive human milk nutrition for premature infants. As the pioneer in human-milk based nutritional products, Prolacta has built the only pharmaceutical-grade manufacturing facility for human breast milk products.
- A 100 percent human milk diet for premature infants weighing less than 1250 grams has resulted in improved health outcomes, and cost savings due to a decrease in the incidence and severity of co-morbidities.^{i, ii, iii, v}

As the Pioneer in Human Milk-Based Nutritional Products, Prolacta has Many Firsts:

- 1st and only commercially available human milk fortifier, **Prolact+ H²MF[®]**, made exclusively from human milk
- 1st and only standardized donor human milk **Prolact HM[®]**
- 1st and only human milk caloric fortifier **Prolact CR[®]**
- 1st and only human milk-based premature infant formula **Prolact RTF[™]**
- 1st and only human milk for trophic feeds **PremieLact[™]**
- 1st and only large-scale donor milk processing facility
- 1st and only breast milk DNA fingerprint for 100 percent donor identification
- 1st and only adulteration, nicotine, and drug screening tests for donated human milk
- 1st and only company to conduct clinical trials on the use of a 100 percent human milk diet for preemies in neonatal intensive care

Prolacta Honors Breastfeeding Mothers and the Nutritional Value of Breast Milk

- Prolacta honors and values breastfeeding mothers for their commitment to the health of babies, and the vital role they play in bringing lifesaving products to infants in the NICU.
- Prolacta offers a variety of programs (milkbanking.net) for moms who wish to donate their excess breast milk to help the most fragile premature babies in neonatal care.

Prolacta Company Overview

Board of Directors

Chairman of the Board

John Bacich Jr., former president, Baxter Bioscience Division

Scott A. Elster, CEO, Prolacta Bioscience

David Brailer, M.D., Ph.D., Health Evolution Partners

Frank H. Foster, Gideon Hixon Fund

Ned Brown, Health Evolution Partners

Dan Janney, Alta Partners

Sally Crawford, former COO, Healthsource

Ernie Strapazon, former president, Nestlé Nutritional Products

Executive Management

Scott A. Elster, Chief Executive Officer

Alan J. Kofsky, VP, Sales and Marketing

Tami D. Ciranna, Chief Financial Officer

Martin L. Lee, Ph.D., VP, Clinical R&D

Scott A. Eaker, VP, Quality and Regulatory

Susan K. Neumann, VP, Milk Procurement

Joseph A. Fournell, VP, Operations

David J. Rechtman, M.D., VP, Medical Affairs

i Sullivan S, et al., "An Exclusive Human Milk-Based Diet is Associated with a Lower Rate of Necrotizing Enterocolitis than a Diet of Human Milk and Bovine Milk-Based Products." *Journal of Pediatrics*. 2010;156(4):562-567

ii Cristofalo E, et al., "Randomized Trial of Exclusive Human Milk versus Preterm Formula Diets in Extremely Premature Infants." *Journal of Pediatrics*. 2013;163(6):1592-1595

iii Hair A, et al., "Randomized Trial of Human Milk Cream as a Supplement to Standard Fortification of an Exclusive Human Milk-Based Diet in Infants 750-1250g Birth Weight." *Journal of Pediatrics*. 2014;165(5):915-920

iv Abrams S, et al., "Greater Mortality and Morbidity in Extremely Preterm Infants Fed a Diet Containing Cow Milk Protein Products." *Breastfeeding Medicine*. 2014;9(6):281-285

v Ganapathy V, et al., "Long Term Healthcare Costs of Infants Who Survived Neonatal Necrotizing Enterocolitis: A Retrospective Longitudinal Study Among Infants Enrolled in Texas Medicaid." *BMC Pediatrics*. 2013;13:127

vi American Academy of Pediatrics, "Breastfeeding and the Use of Human Milk." *Pediatrics*. 2012;129:e827